All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
ICML 2019 | Comments on the addition of lenalidomide to R-CHOP in two studies
During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Marek Trněný, Charles University General Hospital, Prague, CZ, about the impact of the total metabolic tumor volume on the identification of patients who failed treatment while refractory.
He also discusses two randomised trials that investigated lenalidomide and R-CHOP, mentioning that the phase III study failed to show benefits, while results of the phase II trial were positive.
ICML 2019 | Comments on the addition of lenalidomide to R-CHOP in two studies
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox